Quantity signal
Helps estimate the remaining pool of recruitable follicles and likely response to ovarian stimulation.
AMH testing can be useful, but the number is frequently asked to answer questions it cannot answer. For someone considering fertility treatment in Thailand, the useful question is not simply “Is my AMH good?” It is what does my ovarian-reserve picture mean for the treatment decision in front of me?
This guide explains anti-Müllerian hormone (AMH), antral follicle count (AFC), age, ovarian response, IVF planning and the limits of ovarian-reserve testing. It also shows international patients how to compare a Thai fertility provider, specialist and complete current cost without turning one laboratory result into a diagnosis.

AMH is produced by cells surrounding small developing follicles in the ovaries. In fertility care it is commonly used alongside age, ultrasound and clinical history to estimate ovarian reserve and to help anticipate how the ovaries may respond to stimulation medication. A lower result can suggest a lower expected egg yield; a higher result can suggest a stronger response and, in some patients, a need for careful stimulation planning.
That makes AMH valuable for treatment planning. It does not make AMH a stand-alone fertility score. A person with a low AMH can still ovulate and conceive, while a person with a high AMH is not guaranteed pregnancy. Egg quality, sperm, embryo development, uterine factors, tubal factors and age remain important. The result belongs inside a fertility assessment, not on its own.
Helps estimate the remaining pool of recruitable follicles and likely response to ovarian stimulation.
Antral follicle count gives a visual estimate of small follicles and can support or challenge the AMH picture.
Age remains central when discussing egg quality, embryo chromosome risk and realistic treatment expectations.
Previous stimulation response, egg yield, embryo development and pregnancy history can be more informative than a single new number.
Patients are sometimes told that AMH reveals how many eggs they have remaining. That is an oversimplification. The ovaries contain a much larger population of follicles than can be seen or recruited in one treatment cycle. AMH reflects activity from a subset of small growing follicles and correlates with ovarian reserve, but it does not literally count the eggs in the ovaries.
Clinically, AMH is useful because it can help a fertility specialist estimate likely ovarian response. If IVF or egg freezing is being considered, that can influence medication dose, monitoring expectations and conversations about how many eggs might reasonably be retrieved. It may also help identify patients at risk of an excessive response.
The value is therefore practical rather than prophetic. AMH helps plan a cycle. It cannot tell you the exact number of eggs that will be retrieved, how many will be mature, how many will fertilise, how many embryos will reach blastocyst stage or whether an embryo will implant.


This distinction is one of the most important parts of understanding ovarian-reserve testing. AMH is mainly used as a marker of quantity and expected response. It does not directly test the chromosomal quality of an egg. Age is much more closely connected with the probability that an egg is chromosomally normal.
Two patients can therefore have similar AMH results but very different treatment conversations because their ages, histories and goals differ. Likewise, a younger patient with a low AMH and an older patient with the same AMH should not automatically be given the same prognosis.
For international patients comparing IVF in Thailand, ask clinics to explain expected response and expected outcome separately. A statement such as “your AMH is low” is incomplete unless the specialist explains what that means in the context of your age, AFC, previous treatment and intended procedure.
Laboratories may use different assays, units and reference intervals. Avoid taking a threshold from a website and applying it mechanically to a report from another laboratory.
A lower AMH may suggest reduced ovarian reserve and a lower expected response to stimulation. It does not mean there are no eggs and does not by itself prove infertility. The specialist may discuss AFC, age, cycle regularity, previous response and whether treatment timing should be prioritised.
A result within the laboratory's expected range can be reassuring for ovarian response, but it does not rule out other causes of infertility. Tubal, uterine, sperm and embryo factors still matter.
A higher AMH can be associated with a larger recruitable follicle pool. In some patients, including some with polycystic ovarian morphology or PCOS, it may signal the need for careful stimulation to manage excessive response risk.
An antral follicle count is usually obtained by pelvic ultrasound. The clinician counts small follicles visible in the ovaries at the relevant point in the cycle. AFC and AMH often point in the same direction, but they are different measurements and they do not always agree perfectly.
That disagreement can itself be useful. A specialist can review whether timing, laboratory variation, medication, ovarian anatomy or previous surgery might help explain the picture. The ultrasound can also provide information beyond ovarian reserve, including ovarian cysts, fibroids, endometrial appearance or other structural findings relevant to treatment planning.
For someone travelling to Thailand, ask whether the clinic wants an ultrasound performed locally before travel or prefers to perform its own baseline scan. If you already have recent images or reports, send them before booking flights and ask whether they are adequate for preliminary planning.

For a patient who has only just started thinking about fertility, ovarian-reserve testing is information rather than a verdict. The result can open a useful conversation about reproductive goals, age, whether pregnancy is being attempted now and whether fertility preservation is relevant. It should not create false certainty. A reassuring reserve result cannot exclude tubal disease, endometriosis, sperm problems or future age-related decline, while a lower result does not prove that spontaneous conception cannot occur.
For someone already experiencing infertility, AMH has a different role. The clinical question is no longer simply how many follicles might remain; it is how ovarian reserve fits with the reason pregnancy has not occurred and what treatment is proportionate. A lower expected response may make time and treatment efficiency more important, but the specialist still needs to assess ovulation, uterus, tubes and sperm where relevant. Jumping from one low AMH result directly to a treatment package skips the diagnostic reasoning that patients deserve.
For IVF patients, reserve testing becomes operational. It can influence the starting stimulation strategy and the expectations discussed before treatment. Patients should understand that predicted response is a range rather than a promise. Follicles can respond differently from one cycle to another, and the number of eggs retrieved is not the same as the number of mature eggs, fertilised eggs, blastocysts or transferable embryos. Asking the clinic to explain each attrition stage produces a more realistic picture than focusing on the AMH number alone.
For egg-freezing patients, the relationship between quantity and age deserves special attention. Ovarian reserve may help estimate how many eggs could be obtained in a retrieval, while age influences the probability that stored eggs will ultimately produce chromosomally competent embryos and a live birth. A clinic should therefore discuss both how many eggs it expects to collect and why the patient's age changes the meaning of that number. Some patients may discuss more than one retrieval, but that decision should be personalised and costed clearly.
For patients with previous ovarian surgery, endometriosis or other relevant history, reserve testing may help frame a more complex discussion. The location and extent of disease, symptoms, previous surgery, ovarian anatomy and future treatment goals can all matter. A fertility specialist may need to balance treatment urgency, symptom management and preservation of ovarian tissue. This is precisely why a laboratory result should not be interpreted without the clinical history.
For international patients, the best use of AMH is often before travel. A recent result can help a Thai fertility team triage records, anticipate the likely consultation and decide whether additional information is needed. That can make a short diagnostic visit more productive or allow an IVF trip to be planned with fewer surprises. The clinic should still confirm whether it accepts the outside laboratory result and whether it wants its own baseline testing before medication begins.
The quality of communication is part of quality of care. A good explanation distinguishes what is known, what is estimated and what remains uncertain. Patients should leave the consultation understanding the purpose of the test, the limitations of the result, the likely treatment implications and the alternatives. If a provider uses AMH primarily as a sales trigger—especially if it makes absolute claims about pregnancy or insists that one result proves an urgent need for a particular package—that is a reason to ask more questions.
Finally, ovarian reserve is only one part of reproductive medicine. Fertility treatment can involve two patients, several biological stages and multiple clinical disciplines. Sperm quality, fertilisation method, embryology, embryo development, uterine preparation, genetics where appropriate, general health and treatment timing can all affect the pathway. The most useful clinic is not the one that gives the most dramatic interpretation of AMH; it is the one that places the result accurately within the complete treatment decision.
AMH testing may be inexpensive compared with IVF, but the important commercial decision is often what follows the test. Compare the pathway rather than shopping for the cheapest laboratory number.
Choose a fertility service that can connect testing to consultation, ultrasound and the treatment pathway you may need.
Compare providersLook at who interprets the result and who would make the treatment recommendation, not only who orders the blood draw.
Compare specialistsCheck whether the quoted amount covers AMH only, a fertility assessment, ultrasound, consultation or a wider package.
Request current pricing
In IVF and egg freezing, ovarian stimulation aims to recruit multiple follicles during one cycle. AMH can help the specialist estimate response and choose an initial stimulation strategy. A patient expected to respond poorly may need a different discussion from someone expected to produce many follicles.
For lower reserve, the conversation may include realistic egg-yield expectations, whether more than one retrieval could be considered, the value of acting sooner rather than later, and whether previous cycle data should influence the protocol. No medication strategy can manufacture ovarian reserve, so marketing claims that imply a protocol can simply “fix” low AMH deserve scrutiny.
For higher reserve, the priority may include avoiding excessive response. Medication dose, monitoring and trigger strategy can be adjusted by the treating team. The goal is not to produce the maximum possible number of follicles at any cost; it is to pursue an effective cycle while managing risk.
AMH is therefore one planning input among several. The specialist may also use AFC, body size, age, previous stimulation response, diagnosis and treatment objective. A good consultation explains how these inputs fit together.
Treatment in Thailand often means several appointments, with free days or recovery time in between. Plan where you stay, how you spend those days and when you fly — then send it to JLIT alongside your treatment enquiry.
“I cannot get pregnant naturally.”
AMH does not directly measure natural conception probability and does not establish whether ovulation, tubes, sperm and other factors are normal.
“My eggs are poor quality.”
AMH is not an egg-quality test. Age is more relevant to chromosomal risk, although no age alone guarantees an individual embryo outcome.
“I have plenty of time.”
A high AMH does not freeze reproductive ageing. Treatment timing should be discussed in the context of age and goals.
“I definitely need IVF.”
Low reserve may affect urgency or response, but treatment selection depends on the whole fertility assessment.
“A high AMH means IVF will succeed.”
Egg number is only one stage. Fertilisation, embryo development, chromosome status and implantation also matter.
“One result can never change.”
AMH can vary between tests and assays. Meaningful interpretation belongs with the laboratory method, history and clinical picture.
Ovarian-reserve testing may be discussed during infertility assessment, before IVF or ICSI, before egg freezing, after ovarian surgery, or when a patient wants information relevant to reproductive planning. The value depends on what decision the result will inform.
If you are not currently trying to conceive, an AMH test can still provide information about ovarian reserve, but it should not be marketed as a precise fertility forecast. It cannot tell you the exact age at which natural fertility will end. If you are considering egg freezing, the result may be more directly useful because it can help estimate likely stimulation response and frame the number of retrievals that might be discussed.
If you are already pursuing IVF, previous cycle performance may be particularly valuable. Bring medication doses, follicle counts, trigger details, number of eggs retrieved, maturity, fertilisation and embryo-development information. That evidence shows how your ovaries actually responded rather than only predicting response.

Send recent AMH, hormone results, ultrasound reports and previous fertility-treatment records. Ask the Thai provider what it can accept and what it expects to repeat. This reduces duplicated testing and helps the specialist prepare a useful consultation.
A focused visit may combine consultation, AMH or other laboratory testing, pelvic ultrasound and discussion of treatment options. If treatment might start on the same trip, ask about cycle timing before travel.
Obtain copies of results and a written plan. If IVF, egg freezing or further testing is recommended, request an itemised current quotation and provisional timetable before making another travel commitment.

A published AMH-test price can be useful, but it may represent only the laboratory assay. Another provider's “fertility assessment” may include a consultation, ultrasound or additional blood tests. Those are not like-for-like products.
For an international patient, the financially important number is often the cost of the decision pathway: consultation, required tests, imaging, interpretation, treatment recommendation and—if proceeding—the complete treatment quote. IVF pricing should make clear what happens with medication, monitoring, anaesthesia, egg retrieval, laboratory fertilisation, ICSI if indicated, blastocyst culture, embryo freezing, storage, genetic testing and embryo transfer.
JLIT's fertility gateway is designed to connect treatment choice with provider, specialist and published pricing where reliable published pricing exists. Where it does not, request a current quotation rather than relying on an invented estimate.

A well-organised record pack can turn the first appointment from a fact-finding exercise into a decision-making consultation. Include your age, menstrual pattern, how long pregnancy has been attempted, pregnancy history, relevant diagnoses, surgery and medication. Add laboratory reports with dates and units rather than typing isolated numbers into an email.
Where relevant, include AMH, FSH, LH, estradiol, thyroid or prolactin results; pelvic ultrasound and AFC reports; tubal investigations; semen analyses; and records from previous IUI or IVF cycles. For previous IVF, the stimulation protocol and embryology outcomes are especially useful.
Do not worry if you do not have every item. The point is not to order every conceivable test before speaking with the clinic. It is to provide what already exists so the specialist can identify what is missing and avoid unnecessary duplication.
01 Which AMH assay and units does the laboratory use?
02 How does my result compare with the laboratory reference range and my age?
03 Will you perform an antral follicle count as well?
04 Do any medicines or recent treatment affect how you interpret this result?
05 What does the result suggest about expected stimulation response?
06 What does it not tell me about egg quality?
07 How does my age change the interpretation?
08 Do my AMH and AFC agree?
09 If they disagree, how will you investigate that?
10 Do you need any test repeated in Thailand?
11 Can you use my recent results from home?
12 What previous IVF records should I send?
13 Would this result alter an IVF medication protocol?
14 Would it alter an egg-freezing discussion?
15 Does it change treatment urgency in my case?
16 What other fertility factors still need assessment?
17 Who will interpret all results with me?
18 What exactly is included in the quoted assessment price?
19 If treatment is recommended, can I receive an itemised current quotation?
20 What is the next decision after the assessment?
Patients frequently compare results across clinics, countries and online groups. That can be misleading when laboratories use different assays or units. Always keep the original report. A specialist needs the numerical value, unit, date and laboratory reference information.
If a repeat test differs, the correct response is not automatically to assume ovarian reserve changed dramatically. The clinician may consider laboratory method, timing, medication and normal biological or analytical variation. A trend can sometimes be useful, but repeated testing should have a reason rather than becoming a source of anxiety.
For treatment planning, the result is strongest when paired with ultrasound and clinical evidence. The laboratory provides a measurement; the fertility specialist provides interpretation.
Researching fertility treatment abroad can become fragmented: one browser tab for AMH, another for a clinic, another for a doctor, another for IVF prices, then separate searches for flights, accommodation and transfers. JLIT brings those decisions into one pathway.
Start with what you need clinically. We can help you compare the relevant fertility provider and specialist, identify published pricing where it is available, request current pricing where it is not, and organise the practical questions that matter to an international patient. If the assessment leads to IVF, ICSI, egg freezing or another treatment, the same enquiry can carry the treatment and travel requirements forward.
The treating fertility team remains responsible for diagnosis and medical decisions. JLIT's role is to make the Thailand pathway easier to compare and organise: provider, practitioner, price, dates, accommodation, flights, airport transfers and other trip requirements in one place.
Anti-Müllerian hormone is produced by cells associated with small developing ovarian follicles. Fertility specialists use it as one marker of ovarian reserve and expected response to ovarian stimulation. It is not a direct count of eggs and is not a stand-alone test of fertility.
No. A low AMH can indicate reduced ovarian reserve and may predict a lower response during stimulation, but it does not by itself establish infertility or prove that natural conception is impossible. The whole reproductive picture matters.
No. AMH is mainly a quantity and response marker. It does not directly assess whether an individual egg is chromosomally normal. Age remains an important part of discussions about egg quality and embryo chromosome risk.
AMH can help predict ovarian response and potential egg yield, which are relevant to IVF planning, but IVF success depends on many later stages including maturity, fertilisation, embryo development, chromosome status where assessed, uterine factors and implantation.
AFC is an ultrasound count of small follicles visible in the ovaries. It is another ovarian-reserve marker and is commonly interpreted alongside AMH, age and treatment history.
Results do not always align perfectly. A fertility specialist can review the laboratory method, ultrasound timing and quality, medication, ovarian anatomy and previous response before deciding how much weight to give each measurement.
No. A higher AMH can suggest a larger follicle pool and potentially stronger stimulation response, but it does not guarantee pregnancy. In some patients it may also be associated with a risk of excessive ovarian response and requires thoughtful protocol planning.
Yes. AMH may form part of a fertility assessment or fertility-preservation consultation without committing to IVF. The important step is to have the result interpreted for your actual goal rather than treating the test as a treatment recommendation.
Not automatically. Send your existing dated laboratory report to the Thai provider first and ask whether it is sufficiently recent and compatible with its planning. Repeat testing should have a clinical reason.
A focused consultation, blood test and ultrasound can require much less time than a full IVF cycle, but timing depends on the clinic and investigations planned. If you may begin treatment during the same trip, obtain the proposed cycle timetable before booking travel.
Be cautious with claims that a supplement, procedure or protocol can reliably restore ovarian reserve. A fertility specialist should focus on what the result means for timing, treatment strategy and realistic expectations rather than promising to manufacture more reserve.
AMH can help estimate how strongly the ovaries may respond to stimulation and therefore frame expectations about egg yield per retrieval. Age remains crucial because freezing more eggs does not remove age-related differences in egg quality.
Check whether you are comparing a laboratory test with a complete fertility assessment. Ask whether specialist consultation, ultrasound/AFC, other blood tests and interpretation are included. If treatment is proposed, request a separate itemised current treatment quotation.
Yes. The JLIT Fertility gateway connects the treatment or investigation with relevant providers, fertility specialists, published or current pricing and practical Thailand travel requirements.
AMH and ovarian-reserve testing can be extremely useful when they are interpreted properly. They help fertility specialists estimate ovarian response, frame expectations and plan IVF or egg-freezing treatment. They become misleading when a single value is treated as an egg-quality score, a natural-fertility forecast or a guarantee of treatment success.
If you are considering testing or treatment in Thailand, bring the result into a broader assessment. Pair it with age, AFC, reproductive history, partner factors where relevant and previous treatment response. Then ask the practical questions: what does this change, what happens next, who will manage the treatment and what will the complete pathway cost?


A long-term Thailand resident with more than 30 years in international finance. Quick, free and no obligation.
Lawrence or the team will reply within one working day.
Want a faster reply? Message us directly:
Loading today’s eight-stamp reel.
Show the community you love your prize. Give it a heart.
One click adds your heart to the community total.